Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-26T10:02:14.410Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotic Drug-Induced Movement Disorders

Published online by Cambridge University Press:  02 December 2014

Pierre J. Blanchet
Pierre J. Blanchet*
Affiliation:
Department of Stomatology, Faculty of Dentistry, Universite de Montreal, and Andre-Barbeau Movement Disorders Unit, Hôtel-Dieu du CHUM, Montreal, QC, Canada
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Very early in the process of diagnosing abnormal involuntary movement (AIM) disorders, one can be rewarded by keeping a high index of suspicion for possible drug-induced causes, not only through a complete list of current medications, but also identification of the drugs the patient used to take and other possible offending medications that might be available from family members and other sources. Among drug-induced movement disorders, antipsychotic drugs and other dopamine receptor blocking agents occupy a central place. Their various acute and tardive motor complications provide the template of this short review. Movement disorders caused by antidepressants, lithium, antiemetics, antiparkinsonian agents, anticonvulsants, calcium channel blockers, sympathomimetics and others are only briefly covered in table form.

Résumé

RÉSUMÉ

L’une des questions fondamentales dans le diagnostic et la prise en charge des troubles du mouvement est de dérminer si une mécation est en cause. Ceci néssite de toujours rester sur ses gardes et d’obtenir non seulement une liste complè de la mécation actuelle mais aussi une histoire pharmacologique déilléde la mécation antéeure ou disponible auprèdes proches ou d’autres sources. Les antipsychotiques et autres bloqueurs des répteurs dopaminergiques occupent une place dominante au sein des troubles du mouvement iatrogès. Les complications motrices tant aiguëque tardives qu’ils engendrent sont au coeur de cette courte revue. Les troubles du mouvement causépar les antidéesseurs, le lithium, les anti-étiques, les anti-parkinsoniens, les anti-éleptiques, les bloqueurs des canaux calciques, les sympathomiméques et divers autres agents sont abordéseulement sous forme de tableau.

Type
Research Article
Information
Canadian Journal of Neurological Sciences , Volume 30 , supplement S1: A Peer-Reviewed Supplement to the Canadian Journal of Neurological Sciences , February 2003 , pp. S101 - S107
Copyright
Copyright © The Canadian Journal of Neurological 2003

References

1. Owens, DGC. A Guide to the Extrapyramidal Side-Effects ofAntipsychotic Drugs. Cambridge: Cambridge University Press, 1999.Google Scholar
2. Ayd, FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961;175:1054–1060.Google Scholar
3. Singh, H, Levinson, DF, Simpson, GM, Lo, EES, Friedman, E. Acutedystonia during fixed-dose neuroleptic treatment. J Clin Psychopharmacol 1990;10:389–396.Google Scholar
4. Chakos, MH, Mayerhoff, DI, Loebel, AD, Alvir, J, Lieberman, JA. Incidence and correlates of acute extrapyramidal symptoms in first episode of schizophrenia. Psychopharmacol Bull 1992;28:81–86.Google ScholarPubMed
5. Raja, M. Managing antipsychotic-induced acuteand tardivedystonia. Drug Saf 1998;19:57–72.Google Scholar
6. Tune, L, Coyle, JT. Acute extrapyramidal side-effects: serum levelsof neuroleptics and anticholinergics. Psychopharmacology 1981;75:9–15.Google Scholar
7. Eldridge, M. The torsion dystonias: literature review and genetic andclinical studies. Neurology 1970;20:1–78.Google Scholar
8. Swett, C. Drug-induced dystonia. Am J Psychiatry 1975;132:532–534.Google Scholar
9. Sethy, VH, van Woert, MH. Modification of striatal acetylcholineconcentration by dopamine receptor agonists and antagonists. Res Commun Chem Pathol Pharmacol 1974;8:13–28.Google Scholar
10. Neale, R, Gerhardt, S, Liebman, JM. Effects of dopamine agonists,catecholamine depletors, and cholinergic and GABAergic drugs on acute dyskinesias in squirrel monkeys. Psychopharmacology 1984;82:20–26.Google Scholar
11. Sachdev, P, Kruk, J. Clinical characteristics and predisposing factorsin acute drug-induced akathisia. Arch Gen Psychiatry 1994;51:963–974.CrossRefGoogle Scholar
12. Stephen, PJ, Williamson, J. Drug-induced parkinsonism in theelderly. Lancet 1984;2:1082–1083.Google Scholar
13. Sethi, KD, Zamrini, EY. Asymmetry in clinical features of drug-induced parkinsonism. J Neuropsychiatry 1990;2:64–66.Google ScholarPubMed
14. Yassa, R, Samarthji, L. Prevalence of the rabbit syndrome. Am JPsychiatry 1986;143:656–657.Google Scholar
15. Burn, DJ, Brooks, DJ. Nigraldysfunction in drug-inducedparkinsonism: an 18F-dopa study. Neurology 1993;43:552–556.Google Scholar
16. Kornhuber, J, Bormann, J, Hübers, M, Rusche, K, Riederer, P. Effectsof the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel : a human postmortem brain study. Eur J Pharmacol - Mol Pharmacol Sect 1991;206:297–300.Google Scholar
17. Silver, H, Geraisy, N, Schwartz, M. No difference in the effect ofbiperiden and amantadine on parkinsonism- and tardive dyskinesia-type involuntary movements. J Clin Psychiatry 1995;56:167–170.Google ScholarPubMed
18. Chiarello, RJ, Cole, JO. The use of psychostimulants in generalpsychiatry. Arch Gen Psychiatry 1987;44:286–295.Google Scholar
19. Lieberman, JA, Kane, JM, Alvir, J. Provocative tests withpsychostimulant drugs in schizophrenia. Psychopharmacology 1987;91:415–433.CrossRefGoogle ScholarPubMed
20. Fenton, WS, Blyler, CR, Wyatt, RJ, McGlashan, TH. Prevalence ofspontaneous dyskinesia in schizophrenic and non-schizophrenic psychiatric patients. Br J Psychiatry 1997;171:265–268.CrossRefGoogle Scholar
21. Owens, DGC, Johnstone, EC, Frith, CD. Spontaneous involuntarydisorders of movement. Their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch Gen Psychiatry 1982;39:452–461.Google Scholar
22. Degkwitz, R, Wenzel, W. Persistent extrapyramidal side effects afterlong-term application of neuroleptics. In: Brill, H, Cole, JO, Deniker, P, Hippius, H, Bradley, PB,(Eds). Neuro-psycho-pharmacology (International Congress Series no. 129). Amsterdam: Excerpta Medica Foundation, 1967:608–615.Google Scholar
23. Kane, JM, Weinhold, P, Kinon, B, Wegner, J, Leader, M. Prevalence ofabnormal involuntary movements (“spontaneous dyskinesias”) in the normal elderly. Psychopharmacology 1982;77:105–108.Google Scholar
24. Kane, JM, Woerner, M, Lieberman, J. Tardive dyskinesia: prevalence,incidence, and risk factors. J Clin Psychopharmacol 1988;8(AugSuppl):52S–56S.Google Scholar
25. Ganzini, L, Heintz, RT, Hoffman, WF, Casey, DE. The prevalence oftardive dyskinesia in neuroleptic-treated diabetics — a controlledstudy. Arch Gen Psychiatry 1991;48:259–263.Google Scholar
26. Kapitany, T, Meszaros, K, Lenzinger, E, et al. Genetic polymorphismsfor drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998;32:101–106.Google Scholar
27. Lerer, B, Segman, RH, Fangerau, H, et al. Pharmacogenetics oftardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 2002;27:105–119.Google Scholar
28. Fernandez, HH, Krupp, B, Friedman, JH. The course of tardivedyskinesia and parkinsonism in psychiatric inpatients: 14-yearfollow-up. Neurology 2001;56:805–807.Google Scholar
29. Friedman, JH, Kucharski, LT, Wagner, RL. Tardive dystonia in apsychiatric hospital. J Neurol Neurosurg Psychiatry 1987;50:801–803.Google Scholar
30. van Harten, PN, Matroos, GE, Hoek, HW, Kahn, RS. The prevalenceof tardive dystonia, tardive dyskinesia, parkinsonism and akathisia: the Curacao Extrapyramidal Syndromes Study I. Schizophr Res 1996;19:195–203.CrossRefGoogle Scholar
31. Kiriakis, V, Bhatia, KP, Quinn, NP, Marsden, CD. The natural historyof tardive dystonia. A long-term follow-up study of 107 cases. Brain 1998;121:2053–2066.CrossRefGoogle Scholar
32. Stacy, M, Jankovic, J. Tardive tremor. Mov Disord 1992;7:53–57.CrossRefGoogle ScholarPubMed
33. Christensen, E, Moller, JE, Faurbye, A. Neuropathologicalinvestigation of 28 brains from patients with dyskinesia. ActaPsychiat Scand 1970;46:14–23.CrossRefGoogle ScholarPubMed
34. Egan, M, Apud, J, Wyatt, RJ. Treatment of tardive dyskinesia. Schizophr Bull 1997;23:583–609.Google Scholar
35. Delfs, JM, Ellison, GD, Mercugliano, M, Chesselet, MF. Expression ofglutamic acid decarboxylase mRNAin striatum and pallidum in an animal model oftardive dyskinesia. Exp Neurol 1995;133:175–188.Google Scholar
36. Sakai, K, Gao, XM, Hashimoto, T, Tamminga, CA. Traditional andnew antipsychotic drugs differentially alter neurotransmission markers in basal ganglia-thalamocortical neural pathways. Synapse 2001;39:152–160.Google Scholar
37. Sagara, Y. Induction of reactive oxygen species in neurons byhaloperidol. J Neurochem 1998;71:1002–1012.Google Scholar
38. Naidu, PS, Singh, A, Kulkarni, SK. Carvedilol attenuates neuroleptic-induced orofacial dyskinesia: possible antioxidant mechanisms. Br J Pharmacol 2002;136:193–200.Google Scholar
39. Soares, KVS, McGrath, JJ. The treatment of tardive dyskinesia - asystematic review and meta-analysis. Schizophr Res 1999;39:1–16.Google Scholar
40. Adler, LA, Rotrosen, J, Edson, R, et al. Vitamin E treatment fortardive dyskinesia. Arch Gen Psychiatry 1999;56:836-841.Google Scholar
41. Shamir, E, Barak, Y, Shalman, I, et al. Melatonin treatment for tardivedyskinesia: a double-blind, placebo-controlled, crossover study. Arch Gen Psychiatry 2001;58:1049–1052.Google Scholar
42. Tsai, G, Goff, DC, Chang, RW, et al. Markers of glutamatergicneurotransmission and oxidative stress associated with tardive dyskinesia. Am J Psychiatry 1998;155:1207–1213.CrossRefGoogle Scholar
43. König, P, Chwatal, K, Havelec, L, et al. Amantadine versus biperiden:a double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders. Neuropsychobiology 1996;33:80–84.Google Scholar
44. Angus, S, Sugars, J, Boltezar, R, et al. Acontrolled trial of amantadinehydrochloride and neuroleptics in the treatment of tardive dyskinesia. J Clin Psychopharmacol 1997;17:88–91.Google Scholar
45. Roberts, MS, McLean, S, Millingen, KS, Galloway, HM. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J ClinPharmacol 1986;29:703–708.Google Scholar
46. Jankovic, J, Beach, J. Long-term effects of tetrabenazine inhyperkinetic movement disorders. Neurology 1997;48:358–362.Google Scholar
47. Tarsy, D, Kaufman, D, Sethi, KD, et al. An open-label study ofbotulinum toxin A for treatment of tardive dystonia. ClinNeuropharmacol 1997;20:90–93.Google Scholar
48. Lerner, V, Miodownik, C, Kaptsan, A, et al. Vitamin B6 in the treatmentof tardive dyskinesia: a double-blind, placebo-controlled, crossover study. Am J Psychiatry 2001;158:1511–1514.Google Scholar
49. Weetman, J, Anderson, IM, Gregory, RP, Gil, SS. Bilateralposteroventral pallidotomy for severe antipsychotic induced tardive dyskinesia and dystonia. J Neurol Neurosurg Psychiat 1997;63:554–556.Google Scholar
50. Wang, Y, Turnbull, I, Calne, S, et al. Pallidotomy for tardivedyskinesia. Lancet 1997;349:777–778.Google Scholar
51. Trottenberg, T, Paul, G, Meissner, W, et al. Pallidal and thalamicneurostimulation in severe dystonia. J Neurol NeurosurgPsychiatry 2001;70:557–559.CrossRefGoogle Scholar
52. Sutcher, H, Soderstrom, J, Perry, RD. Tardive dyskinesia: dentalprosthetic therapy. Panminerva Med 1998;40:154–156.Google Scholar